VolitionRx is a life sciences company which focuses on developing blood-based tests to diagnose a range of cancers. The Company is involved in the development of epigenetic Nu.Q blood assays based on its Nucleosomics biomarker discovery platform. It also develops HyperGenomics tissue and blood-based tests to determine disease subtype following initial diagnosis and to decide on appropriate therapy, NuQ tests for non-cancer conditions, and NuQ clinical diagnostic products.